A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis

Nancy J. Olsen, Raye H. Brooks, John J. Cush, Peter E. Lipsky, E. William St. Clair, Eric L. Matteson, Kenneth N. Gold, Grant W. Cannon, Christopher G. Jackson, W. Joseph McCune, David A. Fox, Grace Teal, James Gruber, Luis Espinoza, Jacques Caldwell, Micheal Weisman, Sicy Lee, Steven Abramson, Leonard Calabrese, Thomas MedsgerBetty Nelson, Todd Lorenz, Vibeke Strand

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

Objective. To evaluate the efficacy of an anti-CD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA). Methods. A total of 104 evaluable patients were enrolled in a multicenter, double- blind, multiple-dose, placebo-controlled study of CD5-IC. Results. Treatment with CD5-IC in doses up to 8 mg/m2/day for 4 days in 1 month failed to produce marked or prolonged T cell depletion and was no more effective than placebo in ameliorating disease manifestations. An unexpectedly high placebo response was observed in 48% of the patients. Adverse events were correlated with the dose of CD5-IC, but the treatment was generally well-tolerated. Conclusion. At the doses used in this study, CD5-IC was ineffective for treating RA.

Original languageEnglish (US)
Pages (from-to)1102-1108
Number of pages7
JournalArthritis and rheumatism
Volume39
Issue number7
DOIs
StatePublished - Jul 1996

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this